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 FACILITATORS AND BARRIERS TO PRESCRIBING PRE EXPOSURE PROPHYLAXIS (PrEP) FOR THE PREVENTION OF HIV   
TB Flanagan1, MM Graham1, TT Huynh1, DL Luzim1, AK Miller1, DM Nguyen1, Y Shen1, P Jacobson2, JG Larrabee1 MD 





 143 MD, DO, NP and PA, affiliated with Bi-state Primary Care 
Association, NVRH, UVMMC, CVMC, SVMC, VA, etc. returned 
completed surveys. 
Survey: 
 Barriers associated with PrEP prescription were identified. 
 23 question survey was generated based on previous studies to 
assess knowledge about and barriers to prescription of PrEP 




Figure 1. Practitioners’ concerns regarding PrEP prescription A). Ranked by practitioner selection of the top three barriers to prescription of 
PrEP B). Barriers to PrEP prescription ranked by practitioner level of concern on a 5 point scale from “Not Concerned At All” to “Very Concerned” 
Figure 2. Populations who should be offered PrEP Practitioner selection of 
groups for whom PrEP is indicated Figure 3. Vermont regions surveyed Distribution of indices by region 
 To assess Vermont providers’ attitudes towards PrEP and to 
identify barriers to wider implementation of PrEP as a prevention 
strategy. 
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What is PrEP and who gets it? 
 PrEP is the use of medication by individuals to prevent HIV 
contraction, approved in 2012 after demonstrating safety and 
efficacy in the iPrEx study1 and Partners PrEP2 trials. 
 HIV infection risk is 92% lower in patients using PrEP. 
 Truvada®, a combination of tenofovir and emtricitabine taken 
orally daily, is the only approved PrEP regimen and is intended to 
compliment other prevention strategies such as condoms. 
 HIV negative-individuals at risk for exposure to HIV have been 
identified as  men who have sex with men (MSM), IV drug users, 
heterosexuals who have unprotected sex with partners of 
unknown HIV status, and those in serodiscordant relationships3.  
Barriers to PrEP Implementation 
 PrEP is effective when patients adhere; however, both the 
medical community and some high-risk populations have been 
slow to adopt it as an HIV prevention strategy4.  
 Surveys have shown clinicians perceived barriers to PrEP such 
as adverse side effects, viral drug resistance, increased high-risk 
behavior, cost, and training5. 
HIV in Vermont 
 New diagnoses of HIV among Vermont residents has remained 
relatively stable over the last twenty years6. 
 Vermont CARES, a non-profit, offers free and anonymous HIV 
tests and in-person risk-reduction counseling. Clients are 
increasingly asking about PrEP as a prevention strategy, but the 
response from the medical community is difficult to ascertain.  
 Training is the most prevalent concern amongst all 
providers surveyed. Newer doctors show greater 
concern about lack of training than more experienced 
doctors. 
 Cost to Patient is the second most prevalent concern 
 Providers of care to HIV (+) patients expressed more 
concern with long-term safety and drug resistance. 
 Providers who have not provided care to HIV (+) patients 
in the last year were more concerned with time 
 Providers “unwilling” to prescribe PrEP expressed 
greater concern about the de-emphasis of alternative 
HIV interventions with increased prescription of PrEP 
 Nearly 47% of providers consider themselves “not 
confident at all” when asked to assess their confidence 
level around having an informed discussion with patients 
regarding PrEP 
 Of the providers surveyed, 55% were “willing” or “very 
willing” to prescribe PrEP, though only 6% had 
prescribed PrEP in the last 12 months 
 Vermont providers experience modifiable barriers to 
prescribing PrEP. Sharing this data with advocates 
could prompt the development of targeted interventions    
to reduce these barriers.  
 Continuing education regarding PrEP could decrease 
concerns about proper training and increase provider 
confidence about discussing PrEP with patients. 
 Awareness of costs to patients and insurance coverage 
of PrEP may alleviate concerns about the cost of PrEP. 
 RECOMMENDATIONS 
















































HIV-positive Vermonters (2014) as 
an approximate representation of 
the target population (HIV+) : 661 
known cases 
  
Total Surveyed Physicians "Willing" 
or "Very Willing" to Prescribe PrEP 
(PWPP): 79 
  
Total Physicians Surveyed (PS): 143 
    
 
       
    
      
    
 
        
        
   
 
         
